BioCentury
ARTICLE | Company News

Novartis to begin ex-U.S. compassionate use program for Arzerra

January 26, 2018 5:07 PM UTC

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Novartis AG (NYSE:NVS; SIX:NOVN) will begin offering Arzerra ofatumumab to patients outside the U.S. through compassionate use programs. Genmab said that over the past five years, additional CLL drugs have become available to non-U.S. markets, reducing patient size.

For "lost potential" milestone and royalties, Genmab will receive a $50 million lump-sum payment, and will continue to receive royalties on net sales under a 2014 deal (see BioCentury Dec. 8, 2014)...

BCIQ Company Profiles

Genmab A/S

Novartis AG